
🇨🇦 |🔪 @UMJMHSurgery |Future IR resident @VIRTarHeels🩻|Squash Fanatic| Brunch Connoisseur🍳🥞
New York, USA
Joined September 2025
- Tweets74
- Following840
- Followers135
- Likes795
Sandra Gad MD retweeted
Thank you to Priya Mody and her work as the secretary of the @SIR_ECS! Under her guidance the ABR early career exam resources page was launched to help #IRads with their studies. #WomenInMedicine #WomenInMedicineMonth sirweb.org/in-practice/irdr-…
Sandra Gad MD retweeted
Soon, radiology residents will replace radiology AI models.
Pedrini et al (2026) looked at 3 months' worth of CT scans (2,153) interpreted by an on-call resident. 15.4% of them had intracranial hemorrhage (ICH).
The residents had a sensitivity of 96.4% and specificity of 99.6%. The same studies were given to directly to a commercial AI software, which generated heatmaps. The results and heatmaps were separately evaluated as part of the research protocol (aka not available at interpretation time) with sensitivity of 84% and specificity of 94.4%. Performance by AI improved with multiple hemorrhagic types or sites, but did not outperform the resident.
Of 12 FN reports by residents, 6 would have been caught by the model; the attending that overread the preliminary report obviously found all 12.
AI mislabeled 101 cases as FP for ICH. If these were autonomously read, this would have likely led to increased length of stay, follow-up imaging, or inappropriate treatment changes, including discontinuation or non-administration of thrombolytic therapy in patients with ischemia.
The study authors note that the AI FP "typically would not cause confusion with ICH for radiologists interpreting CT scans, as they are easily recognized as various hyperdense intracranial abnormalities not related to ICH."
Take-home points: 1) Clinical deployment studies are increasingly important for medical AI. The commercial model used here was good and well-validated. 2) Perhaps you should hire a Swiss radiology resident to read all your ICH cases, they seem pretty good.
link.springer.com/article/10…
Sandra Gad MD retweeted
Hepatocellular carcinoma is the main pathological type of liver cancer.
A new study investigated whether liver resection can provide survival benefit in patients with advanced hepatocellular carcinoma who respond to systemic therapy: spkl.io/60107OwNG
Sandra Gad MD retweeted
Join us in South Florida for a weekend update on the latest in Clinical Interventional Oncology. Interact, Question, Learn!
🚨 LAST CALL: Today is the final day to submit your abstract to CIO!
📅 Deadline: TONIGHT, July 13 (11:59 PM ET)
Don't miss your shot at oral presentations, ePosters, awards, publication & tuition support.
Submit now 👉 hubs.ly/Q04pljkH0
Sandra Gad MD retweeted
Amanda Rigas, MD, talks with Shakthi K. Ramasamy, MD (@drShakMD), about insights on her path to interventional radiology, the importance of mentorship, her research interests, and what lies ahead for the next generation of IR trainees. evtoday.com/articles/2026-ma…
Sandra Gad MD retweeted
Just in (again, Friday FDA notices): The @US_FDA
approved Capivasertib (oral AKT inhibitor) for metastatic Hormone-Sensitive prostate Cancer with PTEN deficiency (by IHC; 90%+).
4/30: ODAC voted 7-1 for a favorable benefit-risk profile based on the CAPItello-281 Phase III trial results (HR: 0.81)
astrazeneca.com/media-centre…
Another example of personalized medicine in #oncology
With HIF2 inhibitor Belzutifan approval today (xitter.cf/DrChoueiri/status/2065…), it is a great day for #GU Cancer patients
@OncoAlert @AUC3_Official @DanaFarber_GU @PCFnews @OncBrothers @OncLive
JUST IN: @US_FDA approves combo HIF2 inhibitor Belzutifan + PD1 inhibitor Pembrolizumab in adjuvant Kidney Cancer. Approval based on LS022 trial co-led with @tompowles1 presented @ASCO #GU26 adding another approval to @NobelPrize story with @kaelin_lab @DanaFarber @DanaFarber_GU !
Onward ! Great day for patients !
#HIF2 #oncology #labubu
dailynews.ascopubs.org/do/li…
blog.dana-farber.org/insight…
Sandra Gad MD retweeted
Belzutifan + Pembro now @US_FDA ✅ based off LITESPARK-022: PhIII (vs. Pembro) in adj RCC:
- 2.5yrs DFS: 75.8% vs. 68.6% (HR: 0.72)
- mOS NR
- 2.5yrs OS: 95.6% vs. 93.8% (HR: 0.78)
- AEs: 42.2% vs. 17.9% w/ Gr ≥ 3
#MedTwitter #gusm #KidneyCancer @OncoAlert
Sandra Gad MD retweeted
Congrats Dr. Virginie Papadopoulou, named to SWE’s “Women Engineers You Should Know — 2026,” recognizing outstanding leaders in research, industry, education & community impact. 🎉 go.unc.edu/Td4w6
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO

ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
Sandra Gad MD retweeted
How do you get from trauma activation to needle stick in under an hour? Drs. Kavi Krishnasamy, Brian Funaki, Alex Villalobos, and Nima Kokabi explore the protocols, teamwork, and rapid-fire decision-making that have made IR the new frontline for bleeding control: from empiric embolizations to choosing the right agent for every scenario. Efficiency isn’t just a goal, it’s patient care in action.
Watch the full episode here: backtable.com/shows/vi/podca…
This podcast is supported by Okami Medical.
#VI630 #IR #InterventionalRadiology #Trauma #Embolization #SplenicTrauma #GIBleed #LiquidEmbolics
Sandra Gad MD retweeted
First introduced in 2020 our Pregnancy Toolkit has served as a resource for expectant and new mothers in #IRad. Now updated for 2026, the toolkit continues its legacy by offering guidance on declaring pregnancy, maintaining radiation safety and more! sirweb.org/toolkits/ir-pregn…
Sandra Gad MD retweeted
Replying to @_backtable
@_backtable - we have been collecting cases to create a huge on-demand, free resource for everyone. Big thanks to all our guests for continuing to help out!!
Must be on the app to view cases. A great way to share is via playlists!! Here's a playlist of >15 y90 cases! See here!
backtable.com/playlists/d7da…
@AaronFrittsMD @beckcj @bahetimd @JMichaelBarraza
Sandra Gad MD retweeted
SIR 2026 IR Residency Practicum registration is now open!
With a brand-new format, #SIR26RP has tailored tracks and sessions for all #IR trainees.
Learn more about how you can jumpstart your career and join us in Atlanta, Sept. 27–28: sirweb.org/education/events/…
Great talk about the evolving role personalized dosimetry in HCC and liver mets by @ZTBerman @woodhead @shamaryoungmd Dr.Kokabi & Dr.lilly @thegestgroup #InterventionalRadiology #Y90 #HCC #LiverMets #Dosimetry #GEST2026
Sandra Gad MD retweeted
Calling all Interventional Radiology programs and trainees: Please consider completing and sharing this survey on how Interventional Radiology residencies support trainees navigating parenthood.
@SIRspecialists @cirsesociety @KECKSchool_USC @UWRadiology
docs.google.com/forms/d/e/1F…
Sandra Gad MD retweeted
Listen to our amazing episode! Our guests share their experiences and advice ranging from timing of pregnancy, sharing the news, radiation safety, challenges, parental leave, return to work and more!🎧sirweb.org/kinked-wire/episo…
The Kinked Wire podcast Pregnancy in IR co-hosts met in person for the first time at #SIR26TOR @Marie_Hamel17 @womenirads
Science behind the Study: Advances in RAS Therapeutics for Pancreatic Cancer nej.md/4neOTCE
#Oncology #Gastroenterology
Sandra Gad MD retweeted
8 manuscripts written in the last 4 months 📰📰📰📰📰📰📰📰
14 consecutive desk rejects 🚫🚫🚫🚫🚫🚫🚫🚫🚫🚫🚫🚫🚫🚫
2 accepted so far 🎖️🎖️
Everyone is about that K/D ratio, but that is not the way to measure success. Fail boldly and relish the journey, not the finish line!
Sandra Gad MD retweeted
Unc IR integrated residency has an unexpected opening for a rising R3 for a current DR or IR resident in good standing. Email [email protected] to apply!






































